The only potentially curative options for gastric cancer involve endoscopic or surgical resection, with adjunctive systemic ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

NovaBridge Biosciences ( ($NBP) ) just unveiled an update. On January 6, 2026, NovaBridge Biosciences reported updated Phase 1b data showing that ...

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...

In evaluable patients, IMC002 achieved an objective response rate (ORR) of 66.7% (10/15). Survival data were immature at the time of analysis, with a median progression-free survival (mPFS) of 7.0 ...

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO G I), comparing cadonilimab ...

Stand Up To Cancer® (SU2C) and Cancer Research UK announced today new support for a dream team focused on stopping gastric ...

Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based ...

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

Investing.com -- NovaBridge Biosciences (NASDAQ:NBP) stock surged 19% in premarket trading Tuesday after the company reported positive data for its experimental gastric cancer treatment.